drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous, gene-modified CD19-directed CAR T-cell therapy in which a patient’s T cells are retrovirally engineered to express a CD19-specific CAR with CD28 costimulatory and CD3ζ signaling domains; upon CD19 binding the CAR T cells activate, expand, release cytokines, and kill CD19+ targets via perforin/granzyme-mediated cytolysis to eradicate residual B-ALL cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
brexucabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are retrovirally engineered to express a CD19-specific CAR with CD28 costimulatory and CD3ζ signaling domains. Upon binding CD19 on B-lineage cells, the CAR T cells activate, proliferate, release cytokines, and mediate perforin/granzyme-dependent cytotoxicity to eliminate CD19+ leukemic and normal B cells.
drug_name
Tecartus (brexucabtagene autoleucel; KTE-X19)
nct_id_drug_ref
NCT06144606